Treatment of keratoacanthomas with intralesional methotrexate.

Abstract

Multiple modalities exist for the treatment of keratoacanthoma. Excisional surgery is currently the treatment of choice for the majority of keratoacanthomas. This can result in functional and cosmetic defects when large or strategically located lesions are treated. An effective nonsurgical treatment would be desirable in such cases. Intralesional therapy, particularly with 5-fluorouracil, has been shown to be effective in the treatment of keratoacanthomas. Systemic methotrexate has been tried, with variable success. We report an open, noncontrolled study of nine consecutive patients with unusually large or strategically located solitary keratoacanthomas treated successfully with intralesional methotrexate. All lesions responded promptly, with complete resolution after a mean of 3.0 weeks and a mean of 1.7 injections. No side effects occurred, and scarring was minimal. We concluded that intralesional methotrexate is a simple and effective modality for the treatment of select keratoacanthomas and may offer greater efficacy, a more rapid response, decreased pain, and lower cost compared with intralesional 5-fluorouracil.

• Authors: J L Melton, B R Nelson, D B Stough, M D Brown, N A Swanson, T M Johnson
• Journal: Journal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 25 Issue 6 Pt 1 Pg. 1017-23 (Dec 1991) ISSN: 0190-9622 [Print] United States
• PMID: 1810980 (Publication Type: Case Reports, Journal Article)

Chemical References

• Methotrexate

Topics

• Adult
• Aged
• Aged, 80 and over
• Ear Diseases (drug therapy)
• Ear, External
• Eyelid Diseases (drug therapy)
• Female
• Follow-Up Studies
• Hand Dermatoses (drug therapy)
• Humans
• Injections, Intralesional
• Keratoacanthoma (drug therapy, pathology)
• Lip Diseases (drug therapy)
• Male
• Methotrexate (administration & dosage, therapeutic use)
• Middle Aged
• Nose Diseases (drug therapy)
• Remission Induction
• Thoracic Diseases (drug therapy)